Physician profile
Amanda Small
NPI 1588939714
$3,817.10
in general payments reported to CMS, 2019-2025
31 companies · $702 in 2025
The $702 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $415 · 2022: $697 · 2023: $1,502 · 2024: $502 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221 · Education: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.54 |
| Education | $484.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $381.02 | 2023-2025 | Cabometyx |
| Tersera Therapeutics LLC | $360.65 | 2023-2025 | Zoladex, Xermelo |
| Astrazeneca Pharmaceuticals LP | $344.37 | 2023 | Imfinzi, Tagrisso, Enhertu |
| Boston Scientific Corporation | $278.07 | 2021-2023 | |
| Tactile Systems Technology INC | $270.19 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Daiichi Sankyo INC. | $237.93 | 2023-2025 | Enhertu |
| Siemens Medical Solutions USA, INC. | $180.82 | 2021-2022 | |
| Glaxosmithkline, LLC. | $172.30 | 2022-2023 | Jemperli, Zejula |
| Inari Medical, INC. | $164.16 | 2021 | |
| Seagen INC. | $157.40 | 2023 | Padcev |
| Astellas Pharma US INC | $147.68 | 2025 | Vyloy, Xospata, Veozah |
| Genmab U.S., INC. | $147.16 | 2023-2025 | Tivdak |
| E.R. Squibb & Sons, L.L.C. | $145.05 | 2021-2024 | Opdivo, Opdualag |
| Stryker Corporation | $136.20 | 2022 | |
| Gilead Sciences, INC. | $124.14 | 2023-2025 | Trodelvy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $99.75 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Incyte Corporation | $99.00 | 2022 | |
| Eisai INC. | $46.43 | 2025 | |
| Abbvie INC. | $39.67 | 2024-2025 | |
| Caris Mpi, INC. | $35.81 | 2025 | Mi Cancer Seek |
| Celgene Corporation | $32.02 | 2023 | Abecma |
| Janssen Biotech, INC. | $29.48 | 2025 | Tecvayli |
| Taiho Oncology, INC. | $26.02 | 2024 | |
| Sobi, INC | $25.70 | 2025 | |
| Cti Biopharma Corp. | $24.72 | 2023 | Vonjo |
| Pharmacosmos Therapeutics INC. | $20.98 | 2023 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $20.61 | 2023 | Libtayo |
| Radius Health, INC. | $20.46 | 2022 | |
| Pfizer INC. | $18.71 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $16.94 | 2023 | Onivyde |
| Array Biopharma INC | $13.66 | 2025 | Mektovi, Tukysa, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.